Patents Examined by Thomas G. Wiseman
  • Patent number: 4851348
    Abstract: A method for obtaining E. coli cell lines which carry the deoR mutation is described, as well as the cell lines themselves. These cell lines are useful in cell transfection and transformation, as they transfect transform at much higher frequencies than the previously available cell lines.
    Type: Grant
    Filed: July 16, 1986
    Date of Patent: July 25, 1989
    Assignee: Cold Spring Harbor Laboratory
    Inventor: Douglas Hanahan
  • Patent number: 4849350
    Abstract: The present invention presents a DNA containing a synthetic gene for expression of human epidermal cell growth factor of the DNA sequence; ##STR1## The adoption of the DNA of the present invention improves the stability of mRNA, the translation efficiency and the influence of the high-dimensional structure which is determined by the mRNA sequence, and made it possible to produce hEGF efficiently.
    Type: Grant
    Filed: October 4, 1985
    Date of Patent: July 18, 1989
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Taniyama Yoshio, Igarashi Koichi, Marumoto Ryuji
  • Patent number: 4849355
    Abstract: A method is provided for transferring genes into cells which comprises the step of subjecting the mixture of genes to be transferred and the target cells to an electric treatment.
    Type: Grant
    Filed: December 30, 1987
    Date of Patent: July 18, 1989
    Inventor: Tai-Kin Wong
  • Patent number: 4849349
    Abstract: The cDNA of a new proteinase inhibitor was isolated from a cDNA library of human liver biopsy material using a synthetic Oligonucleotide probe. The cDNA can be expressed by introduction of the cDNA to a microbial host on a DNA vector. Analogs of known proteinase inhibitors can be producing by alteration of the cDNA by substituting codons in the active center of the new proteinase inhibitor.
    Type: Grant
    Filed: February 6, 1986
    Date of Patent: July 18, 1989
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Hermann Ragg
  • Patent number: 4844897
    Abstract: Method of treating a tumor in a mammal comprises administering to said mammal an effective anti-tumor amount of proteases originating from microorganisms.Method of treating a tumor in a mammal comprises administering to said mammal an effective anti-tumor amount of a protease originating from a microorganism which protease is chemically modified by one of the following procedures:(a) coupling with a saccharide,(b) introduction of a hydrophobic polymeric group,(c) alteration of electric charge of the protein surface,(d) conjugation with a low molecular weight anti-tumor agent of molecular weight less than 2,000,(e) formation of dimer or oligomer by cross-linking of protease molecules,(f) conjugation with a synthetic polycation,(g) conjugation with a synthetic polyanion, and(h) combination of the above-mentioned procedures.
    Type: Grant
    Filed: September 12, 1986
    Date of Patent: July 4, 1989
    Assignees: Hiroshi Maeda, Amano Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Maeda, Yasuhiro Matsumura, Osamu Asami, Hideyuki Tanaka, Ikuharu Sasaki
  • Patent number: 4845032
    Abstract: The invention relates to a process for the isolation and purification of .alpha.-interferons by (a) dissolution of the interferon-containing crude product in guandine. HCl solution and precipitation by dilution with water and/or (b) by chromatography on an HIC column under renaturing conditions.
    Type: Grant
    Filed: March 21, 1986
    Date of Patent: July 4, 1989
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Rainer Obermeier
  • Patent number: 4843003
    Abstract: A process is provided for producing an ordered series of cloned, circular, DNA molecules containing shortened target DNA segments derived from a long target DNA segment, which are suitable for use in determining the nucleotide sequence of the long target DNA segment, or for targeting specific regions within the target DNA segment. The process includes producing, by molecular cloning, a plurality of double-stranded recombinant DNA molecules each containing: (i) vector DNA; (ii) a sequencing primer binding site; and, (iii) a DNA region having unique endonuclease sites and a long target DNA segment. The sequencing primer binding site is spaced from the long target DNA segment by at least a portion of said DNA region having the unique endonuclease sites. The plurality of double-stranded circular recombinant DNA molecules are cleared using two restriction endonucleases.
    Type: Grant
    Filed: February 17, 1984
    Date of Patent: June 27, 1989
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Steven Henikoff, Richard E. Gelinas
  • Patent number: 4840901
    Abstract: The present invention teaches a restriction endonuclease which recognizes and cleaves palindromic sequence5'Pu G G N C C Py 3'3'Py C C N G G Pu 5'as well as a process for obtaining this endonuclease. One source of the endonuclease is Deinococcus radiophilus DSM 20551 (ATCC 27063). The endonuclease is useful in analysis of DNA molecules.
    Type: Grant
    Filed: May 20, 1988
    Date of Patent: June 20, 1989
    Assignee: Boehringer Mannheim GmbH
    Inventors: Rudiger Grosskopf, Christoph Kessler
  • Patent number: 4839283
    Abstract: A method is provided for expressing human alpha-1-antitrypsin in yeast utilizing a wild-type strain and a hyperproduction mutant, GK100.
    Type: Grant
    Filed: December 30, 1986
    Date of Patent: June 13, 1989
    Assignee: ZymoGenetics, Inc.
    Inventors: Glenn H. Kawasaki, Richard Woodbury
  • Patent number: 4839284
    Abstract: Disclosed herein is a method for amplifying and expressing transferred genes by temperature induction.
    Type: Grant
    Filed: May 16, 1985
    Date of Patent: June 13, 1989
    Assignee: New York University
    Inventors: Francis G. Kern, Claudio Basilico
  • Patent number: 4837149
    Abstract: Disclosed are compounds of the formula ##STR1## wherein R represents hydrogen or C.sub.1 -C.sub.4 -alkyl. These compounds are obtained by fermentation of the known saframycin A producing strain Streptomyces lavendulae No. 314 and by reaction with the amino acids L-tyrosine, L-methionine, glycine and HOOC-(CH)NH.sub.2 -CH.sub.2 -R. When R is hydrogen, saframycin Y.sub.3 and when R is methyl, saframycin Y.sub.d-1 are produced.
    Type: Grant
    Filed: September 22, 1987
    Date of Patent: June 6, 1989
    Assignee: Tadashi Arai
    Inventors: Tadashi Arai, Yuzuru Mikami
  • Patent number: 4833080
    Abstract: Regulation of eucaryotic gene expression is controlled by procaryotic peptides. The peptides recognize specific DNA sequences present in the gene, which may be derived from procaryotic genes, and either activate or repress gene transcription. Hybrid procaryotic peptides may be used containing both repressor and activator peptides.
    Type: Grant
    Filed: December 12, 1985
    Date of Patent: May 23, 1989
    Assignee: President and Fellows of Harvard College
    Inventors: Roger Brent, Mark S. Ptashne
  • Patent number: 4833086
    Abstract: The subject invention concerns a novel plasmid and its use in a microbial host to degrade a variety of organic compounds. Some of these compounds, such as ethylene dichloride, are undesirable waste products found in various dump sites. The invention also concerns a novel microbe hosting the novel plasmid. The novel plasmid has been shown to encode the gene(s) responsible for the degradation of the organic compounds. Thus, microbes hosting this plasmid, denoted pEDC, can be used to degrade ethylene dichloride, and other compounds.
    Type: Grant
    Filed: March 21, 1986
    Date of Patent: May 23, 1989
    Assignee: The B F Goodrich Company
    Inventor: Amikam Horowitz
  • Patent number: 4833082
    Abstract: A restriction enzyme, ApaLI, which recognizes the base sequence in a double-stranded deoxyribonucleic acid molecule as shown below, and cleaves it at the arrow-marked sites, ##STR1## wherein A, G, T and C represent adenosine, guanosine, thymidine and cytidine, respectively. Also provided is a process for producing this enzyme, by growing a microorganism belonging to the genus Acetobacter.
    Type: Grant
    Filed: September 10, 1986
    Date of Patent: May 23, 1989
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Yuzo Yamada, Makoto Murakami
  • Patent number: 4828994
    Abstract: Bacillus strains having reduced levels of extracellular protease are produced by replacing the native chromosomal DNA sequence comprising the gene for an extracellular protease, such as subtilisin, with a partially homologous DNA sequence having an inactivating DNA segment inserted therein. The strains are useful as hosts for the expression and secretion of heterologous polypeptides or proteins.
    Type: Grant
    Filed: May 13, 1985
    Date of Patent: May 9, 1989
    Assignee: Genex Corporation
    Inventors: Stephen R. Fahnestock, Kathryn E. Fisher
  • Patent number: 4828998
    Abstract: The strain Streptomyces coelicolor DSM 3030 excretes into the fermentation medium high yields of a bacteriolytic enzyme product which is very active against Gram-positive and Gram-negative bacteria. Preferred fermentation media contain sugar beet molasses and/or calcium ions.
    Type: Grant
    Filed: November 6, 1985
    Date of Patent: May 9, 1989
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Gerhard Wohner, Hartmut Voelskow, Paul Prave, Erich Luck, Gert-Wolfhard von Rymon Lipinski
  • Patent number: 4829000
    Abstract: The present invention discloses a biologically active basement membrane composition. When polymerized under physiological conditions, the composition forms gel-like structures whose ultrastructure resembles interconnected thin sheets of the lamina densa zone of basement membrane. The major components of the composition include laminin, type IV collagen, heparin sulfate proteoglycan, entactin and nidogen. These components polymerize in constant proportions when redissolved and allowed to reconstitute. Molecular sieve studies on the soluble extract demonstrate that laminin, entactin and nidogen are associated in a large but dissociable complex. The reconstituted matrix is biologically active and stimulates the growth and differentiation of a variety of cells, including epithelial cells, nerve cells, hair follicles and the like. The reconstituted matrix can also be used for determining metastatic potential of tumor cells and for isolating metastatic tumor cells.
    Type: Grant
    Filed: May 27, 1986
    Date of Patent: May 9, 1989
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Hynda K. Kleinman, George R. Martin
  • Patent number: 4828987
    Abstract: Recombinant DNA molecules in which an avian retroviral long terminal repeat (LTR) has been ligated to the bovine growth hormone gene are described herein. The retroviral LTR was derived from a plasmid clone of a Schmidt Rupin strain of Rous Sarcoma Virus while the bovine growth hormone (BGH) gene was derived from a lambda-bacteriophage genomic library. Using a transient eucaryotic expression assay system, the plasmid constructs were screened for their ability to direct expression and secretion of bovine growth hormone. These constructs were co-transformed into a mammalian cell (mouse) culture in order to obtain a stable cell culture secreting large amounts of bovine growth hormone.
    Type: Grant
    Filed: May 14, 1984
    Date of Patent: May 9, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Kopchick, Frederick C. Leung, Thomas J. Livelli, Richard H. Malavarca
  • Patent number: 4826764
    Abstract: The invention concerns the intercistronic DNA sequence of the atp operon of Escherichia coli for the subunit c of the ATP synthase, a DNA structure and an expression vector which are characterized by the said intercistronic DNA sequence, and a process for the production of proteins using the same. The DNA sequence enhances the rate of synthesis of the proteins.
    Type: Grant
    Filed: July 17, 1985
    Date of Patent: May 2, 1989
    Assignee: Gesellschaft fur Biotechnologische Forschung mbH
    Inventor: Walter Sebald
  • Patent number: 4824782
    Abstract: This invention relates to a DNA base sequence, capable of increasing the amount of protein secreted by microorganisms, and its derivative sequences; a recombinant plasmid including the whole or a part of said DNA base sequence; a method for preparing the recombinant plasmid in which, when microorganisms having introduced thereinto a recombinant DNA including the desired DNA base sequence are to be separated in the process of cloning, suitable transformants can be efficiently selected by taking the amount of protein secreted out of the cells and particularly the activity of an enzyme protein as an index; and a method of microbial breeding which comprises introducing the recombinant plasmid into a microorganism to increase the amount of protein secreted by the microorganism.
    Type: Grant
    Filed: April 8, 1988
    Date of Patent: April 25, 1989
    Assignees: Agency of Industrial Science and Technology, Ministry of International Trade and Industry
    Inventors: Yoshio Furutani, Noboru Tomioka, Masaru Honjo, Kazuaki Manabe, Hiroaki Shimada